What Bristaflam Treats: Main Uses and Benefits

Bristaflam (Aceclofenac) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) used in situations involving certain distressing symptoms related to inflammatory or irritative states of musculoskeletal and joint conditions. Its primary therapeutic role is focused on providing symptomatic relief for adults.

The medication is commonly used across conditions presenting with systemic or localized discomfort, including Rheumatoid Arthritis, Ankylosing Spondylitis, and Osteoarthritis. It is also applied in acute scenarios to assist with the management of pain and swelling following soft tissue injuries or post-dental procedures.

The drug helps address symptom clusters that may become intense or disruptive, such as persistent pain, joint swelling, and significant stiffness. This action contributes to improved day-to-day comfort and supports patients during episodes of heightened discomfort.

“Bristaflam is relevant when supportive symptom management is appropriate for easing challenging symptoms that create noticeable functional strain.”

---

Quick Fact: Focus on Easing Functional Strain
Bristaflam is relevant for easing challenging symptoms, such as pronounced joint stiffness and restricted movement, to support the maintenance of functional stability during symptomatic phases.

---

Bristaflam (Aceclofenac) is officially indicated for use only in the adult population. Regulatory documents establish strict, non-negotiable rules for eligibility, defining populations who are prohibited from use (contraindicated) and those who require careful monitoring.

Contraindicated Populations (Must Not Use)

Use of Bristaflam is strictly prohibited if a patient has:

• Hypersensitivity to Aceclofenac or any other Non-Steroidal Anti-Inflammatory Drug (NSAID) (including those who have experienced asthma, rhinitis, or angioedema after taking aspirin or other NSAIDs).
• Active or recurrent peptic ulcer/haemorrhage (two or more distinct episodes).
• Severe Hepatic (liver) or Severe Renal (kidney) Failure.
• Established Cardiovascular Disease, including Ischaemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA Class II–IV).
• Active bleedings or known bleeding disorders.

Age and Physiological Restrictions

Population Group	Eligibility Status (Regulatory Label)
Pediatric (Under 18)	Not Recommended (Safety and efficacy data not established)
Third Trimester of Pregnancy	Contraindicated
Breastfeeding	Not Recommended (Lack of data on secretion into milk)
Mild-to-Moderate Impairment	Requires Caution and surveillance (e.g., mild renal impairment, mild hepatic impairment)

Eligibility also requires careful consideration for elderly patients and individuals with established cardiovascular risk factors (e.g., uncontrolled hypertension, diabetes).

Interactions with other medicines and products

Official regulatory information outlines specific documented interaction patterns for Bristaflam (Aceclofenac).

Interaction-Related Restrictions

Classification	Interacting Agents	Official Statement of Outcome
Contraindicated	Other systemic NSAIDs and Aspirin at analgesic doses	Increased risk of severe gastrointestinal adverse effects.
Requires Caution	Anticoagulants (e.g., Warfarin), Antiplatelet agents, SSRIs, Corticosteroids	Increased pharmacodynamic risk of bleeding and ulceration.

Documented Exposure and Effect Modifications

Co-administration with certain medicines may alter their concentration in the body or diminish their therapeutic effects:

• Exposure Increased: Bristaflam decreases the elimination of substances like Lithium and Methotrexate, resulting in officially documented increased serum concentrations of these medicines.
• Effect Reduced: Co-use with Anti-hypertensives (ACE inhibitors, ARBs) and Diuretics may result in a reduction of their intended therapeutic effects.
• Nephrotoxicity Risk: Combination with agents like Ciclosporin and Tacrolimus is associated with an increased potential for kidney-related toxicity.

Timing and Population Notes

A time-separation rule exists, stating that use of this medicine is not recommended for 8–12 days following the administration of Mifepristone. Furthermore, the co-administration with Anti-hypertensives presents an increased risk of acute renal insufficiency for elderly or volume-depleted patients. Close medical surveillance is advised for individuals who consume alcohol regularly due to an increased risk of gastric bleeding.

Ikappa Balpha and NF-kappa B Pathway Modulation

Bristaflam operates at the intracellular level. Its active component, Flama-A, is internalized and targets the Ikappa Balpha (Inhibitor of NF-kappa B) complex.

Bristaflam binds allosterically at the Ikappa Balpha site, which modifies the conformation of the complex and stabilizes the interaction between Ikappa Balpha and the NF-kappa B transcription factor. This action prevents the phosphorylation and subsequent ubiquitination of Ikappa Balpha, inhibiting its degradation. As a result, the NF-kappa B complex remains sequestered in the cytoplasm.

The restricted nuclear translocation of NF-kappa B modulates the NF-kappa B pathway, resulting in the modulation of inflammatory cytokine production. This process impacts pathways involved in bone and joint tissue homeostasis, which influences inflammatory effects on structural integrity.

How to Use Bristaflam

The administration of Bristaflam (Aceclofenac) follows established clinical protocols to ensure consistent and controlled use. The general approach follows the core guidelines for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): to use the lowest effective dose for the shortest duration necessary to manage symptoms. The continued necessity of treatment is subject to periodic re-evaluation.

---

Administration Protocol

Usage Parameter	Standard Protocol
Route of Administration	Oral administration as a film-coated tablet.
Standard Adult Dose	The maximum daily dose is 200 mg. This is taken as two separate 100 mg doses per day.
Timing & Preparation	The tablet must be swallowed whole with a sufficient quantity of liquid, and should not be crushed or chewed. Ingestion is recommended with or after food.
Use in Older Adults	No dose modification is typically required for the elderly, though the lowest dose principle must be maintained.
Dose Adjustments	An initial daily dose of 100 mg is suggested for patients with mild hepatic impairment. Use in children under 18 is not recommended due to insufficient clinical data.
Handling Missed Doses	If a dose is missed, a double dose should not be taken; the next dose is taken at the usual scheduled time.

---

These parameters define the standardized, high-level approach for administering Aceclofenac, covering the maximum permissible dosing, frequency, and specific physical requirements for tablet intake.

Research Evidence / Overview of Studies for Bristaflam

The research base for Bristaflam (Aceclofenac) consists primarily of controlled clinical trials, including randomized studies and meta-analyses, which contribute to the contextualization of how symptoms change in groups of patients with certain conditions. This evidence describes group patterns under specific research conditions and does not determine whether an individual will respond similarly.

Research Evidence for Osteoarthritis and Related Joint Conditions

Research has explored Osteoarthritis (OA), a condition characterized by functional limitations. The majority of evidence comes from short-term, randomized controlled trials (RCTs) and systematic reviews that compile these findings. These trials monitored patient-reported outcomes evaluating changes in pain intensity and functional outcomes related to daily activity level. Findings describe patterns observed in the studies related to measured changes in pain compared to placebo or other NSAIDs.

Research Evidence for Rheumatoid Arthritis and Ankylosing Spondylitis

For conditions involving periods of heightened symptoms such as Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), research examined how symptoms evolved in the observed populations. These studies were primarily controlled comparative trials and RCTs that explored short-term symptom patterns. They monitored outcomes linked to inflammatory states, such as the number of swollen or tender joints and changes in functional capacity scores. The research provides context but not individual predictions regarding long-term effects on disease progression.

Research Evidence for Acute and Chronic Musculoskeletal Pain

The evidence base here includes randomized, double-blind trials where measured pain reduction was a primary focus. These studies explored short-term symptom changes, monitoring outcomes related to physical discomfort. Research describes measurable changes in pain intensity and functional disability scores in adult patients with acute pain episodes. A key limitation is that the follow-up durations were very short, sometimes ten days or less.

What Remains Uncertain About Bristaflam Research

Reviewers have noted several areas where the evidence quality varies across studies. The primary limitations include the short duration of many core symptomatic trials, which means long-term effects are not fully established. Furthermore, subgroup findings are uncertain due to limited information for certain patient groups.

Key Studies & References

1. Public Assessment Report for Aceclofenac 100 mg film-coated Tablets (HPRA)
2. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis (Ward et al., 1995)
3. A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders (Varela et al., 2021)

Common questions about Bristaflam (FAQ)

Q: How long does the course of treatment with Bristaflam usually last?

Official guidelines recommend using the medicine at the lowest effective dose for the shortest duration necessary to control symptoms. The necessity of continuing treatment must be re-evaluated periodically by a healthcare provider. This guidance helps frame the use of the medicine.

---

Q: Does Bristaflam cause drowsiness or affect sleep patterns?

Regulatory documents mention that adverse effects reported during use include central nervous system effects such as dizziness and drowsiness. Individuals are generally advised to note how the medicine affects their alertness.

---

Q: Are there any specific foods or drinks, like alcohol or grapefruit juice, that should be avoided with Bristaflam?

Official product information states that co-administration with alcohol is generally not recommended due to an increased risk of gastric bleeding. The tablets are described as being taken with or after food, as food generally affects the rate at which the medicine is absorbed, but not the overall amount.

---

Q: How quickly does Bristaflam typically begin to work after the first use?

According to official pharmacokinetic data, the active ingredient typically reaches its peak concentration in the bloodstream approximately 1.25 to 3.00 hours after the tablet is ingested. This timeline serves as a guide for the medicine's expected onset of action.

---

Q: What is the expected duration of effect after taking Bristaflam?

Official data, which describes how the drug moves through the body, indicates that the active ingredient has a mean plasma elimination half-life of approximately 4 hours. This measurement helps describe the rate at which the active ingredient leaves the bloodstream.

---

Q: Does Bristaflam have a generic version available yet?

Yes, the active component is Aceclofenac, which is an International Nonproprietary Name (INN). The active ingredient is available globally under various generic and brand names besides Bristaflam.

---

Q: Is Bristaflam classified as a controlled substance?

No, the active ingredient is officially classified as a non-narcotic, non-steroidal anti-inflammatory drug (NSAID). This classification means it is not included in the official lists of controlled substances.

---

Q: Why is Bristaflam only available with a prescription?

Bristaflam is classified as a Prescription Only Medicine because of its potency and the inherent risk of serious side effects, particularly cardiovascular and gastrointestinal complications. For these reasons, its use requires medical supervision and is subject to careful medical monitoring.

---

Q: Are there any special laboratory tests or monitoring needed while using Bristaflam?

Regulatory documents describe that monitoring is generally required for patients on long-term treatment as a precautionary measure. This may include checks on kidney function, liver function (liver enzymes), and blood counts.

---

Q: Has Bristaflam been approved for use outside of the United States?

Yes, official records show that the active ingredient was first approved in the European Union (EU) and has since been approved for use in numerous countries worldwide.

---

Q: What are the general recommendations for stopping the use of Bristaflam?

Official guidance does not provide a specific method for cessation but emphasizes that the necessity of continued use must be re-evaluated periodically. The decision to stop use is typically guided by this periodic re-evaluation process.

---

Q: How long does it take for Bristaflam to be completely cleared from the body?

Official pharmacokinetic data states that the mean plasma elimination half-life of the active ingredient is approximately 4 hours. This time frame is the data point regulatory bodies use to determine the rate at which the body clears the medicine.

---

Q: Are there any professional activities like driving or operating machinery that should be avoided while on Bristaflam?

Official product information contains a warning that individuals who experience side effects like dizziness, vertigo, or other central nervous system disturbances should refrain from driving or operating dangerous machinery.

---

Q: What is the most recent research evidence or data available for Bristaflam?

The safety and efficacy profile of the medicine are under continual review by regulatory bodies and are updated based on post-marketing surveillance and ongoing research. The purpose of this review is to maintain a current risk-benefit profile.

How to Store and Dispose of Bristaflam

Official regulatory documents define specific, mandatory requirements for storing and disposing of this medication.

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C. Do not store above 30°C.
Protection	Keep in the original package to protect from light and moisture.
Safety	Keep out of the reach of children; store the product locked up.

Disposal Instructions

Proper disposal is required due to environmental toxicity warnings associated with the active substance.

• Do not flush the medication down the toilet or discard it in household trash.
• Dispose of unused or expired product via an approved waste disposal facility or according to local pharmaceutical take-back programs.
• Avoid release to the environment.